Equipped with multiple “self‐recognized” proteins (such as CD47), the platelet membrane was reported to significantly inhibit phagocytosis‐mediated bloodstream clearance and particle‐induced complement activation, leading to a prolonged plasma half‐life of nanoparticles.[52, 97] The long‐circulating properties, together with the tumor‐targeting ability (mentioned in Section 2.2), make platelet plasma membrane‐coated nanoparticle an ideal platform to transport cargos to tumor sites and act as an in situ cancer vaccine. The gene discussed is CD47; the disease is neoplasm.